HONG KONG: Chinese state-owned Sinopharm plans to inject 30 billion yuan ($4.6 billion) in assets into unit Beijing Tiantan Biological Products Corp Ltd to quickly get its fast-growing vaccine business on the public market, two people told Reuters.
Sinopharm aims to begin the injection of six vaccine-focused biological products developers including makers of two COVID-19 vaccines into Shanghai-listed Tiantan in the coming weeks, said the people plus two other people with knowledge of the matter.
Already a subscriber? Log in.
Save 30% and win Bosch appliances! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
